医学における研究とレポート

The Use of Biomarkers to Guide Precision Treatment for Tobacco Use

Abstract

Scott Siegel*

This survey sums up the proof to date on the improvement of biomarkers for customizing the pharmacological treatment of burnable tobacco use. To begin, the most recent research on medications that have been approved by the FDA is taken into consideration. This research demonstrates that, despite the fact that these medications have real benefits, approximately two-thirds of the time, they do not contribute to smoking cessation. Second, the case for utilizing biomarkers to direct tobacco treatment is made in view of the possibility to increment medicine viability and takeup and diminish aftereffects. Then, the FDA system of biomarker improvement is introduced alongside the condition of science on biomarkers for tobacco treatment, including a survey of the nicotine metabolite proportion, electroencephalographic occasion related possibilities, and other biomarkers used for risk criticism. We conclude with a discussion of the difficulties and opportunities associated with translating biomarkers into treatment guidelines for tobacco use and recommendations for future research priorities.